View Item 

Show simple item record

Improvement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders
dc.contributor.authorRangan, Vikram
dc.contributor.authorSingh, Prashant
dc.contributor.authorBallou, Sarah
dc.contributor.authorHassan, Rafla
dc.contributor.authorYu, Vanessa
dc.contributor.authorKaton, Jesse
dc.contributor.authorNee, Judy
dc.contributor.authorIturrino, Johanna
dc.contributor.authorLembo, Anthony
dc.date.accessioned2022-04-08T18:03:42Z
dc.date.available2023-05-08 14:03:41en
dc.date.available2022-04-08T18:03:42Z
dc.date.issued2022-04
dc.identifier.citationRangan, Vikram; Singh, Prashant; Ballou, Sarah; Hassan, Rafla; Yu, Vanessa; Katon, Jesse; Nee, Judy; Iturrino, Johanna; Lembo, Anthony (2022). "Improvement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders." Neurogastroenterology & Motility (4): n/a-n/a.
dc.identifier.issn1350-1925
dc.identifier.issn1365-2982
dc.identifier.urihttps://hdl.handle.net/2027.42/172007
dc.description.abstractBackgroundAbdominal pain is a bothersome and lifestyle limiting symptom in patients with functional bowel disorders. It is associated with decreased quality of life in affected individuals, as well as significant annual healthcare expenditure. Knowledge of specific factors that predict improvement in abdominal pain in those with functional bowel disorders is thus far limited.MethodsConsecutive patients presenting for outpatient care at a major academic medical center between October 2017 and March 2020 completed an electronic symptom survey prior to initial clinic visit, and again after 3 months. The Rome IV questionnaires for functional dyspepsia, irritable bowel syndrome, functional constipation, and functional diarrhea were all included. Additionally, all subjects completed the Patient Reported Outcomes Measurement Information System Anxiety, Depression, and sleep disturbance questionnaires. Patients with a diagnosis of a Rome IV functional gastrointestinal disorder without any organic cause for symptoms were identified based on both chart review as well as survey response data. Univariable and multivariable analysis was used to assess predictors of improved abdominal pain after 3 months.Key Results180 patients with a mean age of 45.3 years were included in the final analysis. 78.3% of patients were female, and 77.2% met Rome IV criteria for irritable bowel syndrome. On multivariable analysis, improvement in constipation and diarrhea were both independent predictors of improved abdominal pain after 3 months.Conclusions and InferencesImprovement in constipation and diarrhea both predicted improvement in abdominal pain, suggesting that addressing these factors is central to the management of abdominal pain in functional gastrointestinal disorders.Increased baseline abdominal pain, improvement in constipation, and improvement in diarrhea were all independent predictors of improved abodminal pain over a 3 month period.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherabdominal pain
dc.subject.otheranxiety
dc.subject.otherconstipation
dc.subject.otherdiarrhea
dc.subject.otherfunctional dyspepsia
dc.subject.otherirritable bowel syndrome
dc.subject.othersleep disturbance
dc.titleImprovement in constipation and diarrhea is associated with improved abdominal pain in patients with functional bowel disorders
dc.typeArticle
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialties
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172007/1/nmo14253.pdf
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/172007/2/nmo14253_am.pdf
dc.identifier.doi10.1111/nmo.14253
dc.identifier.sourceNeurogastroenterology & Motility
dc.identifier.citedreferenceAgrawal A, Houghton LA, Lea R, Morris J, Reilly B, Whorwell PJ. Bloating and distention in irritable bowel syndrome: the role of visceral sensation. Gastroenterology. 2008; 134 ( 7 ): 1882 ‐ 1889.
dc.identifier.citedreferenceBlack CJ, Yuan Y, Selinger CP, et al. Efficacy of soluble fibre, antispasmodic drugs, and gut‐brain neuromodulators in irritable bowel syndrome: a systematic review and network meta‐analysis. Lancet Gastroenterol Hepatol. 2020; 5 ( 2 ): 117 ‐ 131.
dc.identifier.citedreferenceLacy BE, Pimentel M, Brenner DM, et al. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021; 116 ( 1 ): 17 ‐ 44.
dc.identifier.citedreferenceJohnston JM, Kurtz CB, Macdougall JE, et al. Linaclotide improves abdominal pain and bowel habits in a phase IIb study of patients with irritable bowel syndrome with constipation. Gastroenterology. 2010; 139 ( 6 ): 1877 ‐ 1886.e2.
dc.identifier.citedreferenceBrenner DM, Fogel R, Dorn SD, et al. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018; 113 ( 5 ): 735 ‐ 745.
dc.identifier.citedreferenceLacy BE, Nicandro JP, Chuang E, Earnest DL. Alosetron use in clinical practice: significant improvement in irritable bowel syndrome symptoms evaluated using the US Food and Drug Administration composite endpoint. Therap Adv Gastroenterol. 2018; 11: 1756284818771674.
dc.identifier.citedreferenceBrenner DM, Sayuk GS, Gutman CR, et al. Efficacy and safety of eluxadoline in patients with irritable bowel syndrome with diarrhea who report inadequate symptom control with loperamide: RELIEF phase 4 study. Am J Gastroenterol. 2019; 114 ( 9 ): 1502 ‐ 1511.
dc.identifier.citedreferenceStanghellini V, Chan FKL, Hasler WL, et al. Gastroduodenal disorders. Gastroenterology. 2016; 150 ( 6 ): 1380 ‐ 1392.
dc.identifier.citedreferenceMearin F, Lacy BE, Chang L, et al. Bowel disorders. Gastroenterology. 2016; 150: 1393 ‐ 1407.
dc.identifier.citedreferenceKhanna D, Hays RD, Shreiner AB, et al. Responsiveness to change and minimally important differences of the patient‐reported outcomes measurement information system gastrointestinal symptoms scales. Dig Dis Sci. 2017; 62 ( 5 ): 1186 ‐ 1192.
dc.identifier.citedreferenceSpiegel BMR, Hays RD, Bolus R, et al. Development of the NIH patient‐reported outcomes measurement information system (PROMIS) gastrointestinal symptom scales. Am J Gastroenterol. 2014; 109 ( 11 ): 1804 ‐ 1814.
dc.identifier.citedreferenceChapman RW, Stanghellini V, Geraint M, Halphen M. Randomized clinical trial: macrogol/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome. Am J Gastroenterol. 2013; 108 ( 9 ): 1508 ‐ 1515.
dc.identifier.citedreferenceGarsed K, Chernova J, Hastings M, et al. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014; 63 ( 10 ): 1617 ‐ 1625.
dc.identifier.citedreferenceJohanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2008; 27 ( 8 ): 685 ‐ 696.
dc.identifier.citedreferenceDrossman DA, Chey WD, Johanson JF, et al. Clinical trial: lubiprostone in patients with constipation‐associated irritable bowel syndrome–results of two randomized, placebo‐controlled studies. Aliment Pharmacol Ther. 2009; 29 ( 3 ): 329 ‐ 341.
dc.identifier.citedreferenceKanazawa M, Palsson OS, Thiwan SIM, et al. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol. 2008; 103 ( 10 ): 2550 ‐ 2561.
dc.identifier.citedreferenceYang Y, Fang J, Guo X, et al. Linaclotide in irritable bowel syndrome with constipation: a phase 3 randomized trial in China and other regions. J Gastroenterol Hepatol. 2018; 33 ( 5 ): 980 ‐ 989.
dc.identifier.citedreferenceChen L, Ilham SJ, Feng B. Pharmacological approach for managing pain in irritable bowel syndrome: a review article. Anesth Pain Med. 2017; 7 ( 2 ): e42747.
dc.identifier.citedreferenceChang L, Chey WD, Drossman D, et al. Effects of baseline abdominal pain and bloating on response to lubiprostone in patients with irritable bowel syndrome with constipation. Aliment Pharmacol Ther. 2016; 44 ( 10 ): 1114 ‐ 1122.
dc.identifier.citedreferenceBallou S, Beath A, Kaptchuk TJ, et al. Factors associated with response to placebo in patients with irritable bowel syndrome and constipation. Clin Gastroenterol Hepatol. 2018; 16 ( 11 ): 1738 ‐ 1744.e1.
dc.identifier.citedreferenceWhitehead WE, Palsson OS, Levy RL, Feld AD, VonKorff M, Turner M. Reports of “satisfactory relief” by IBS patients receiving usual medical care are confounded by baseline symptom severity and do not accurately reflect symptom improvement. Am J Gastroenterol. 2006; 101 ( 5 ): 1057 ‐ 1065.
dc.identifier.citedreferencePassos MCF, Lembo AJ, Conboy LA, et al. Adequate relief in a treatment trial with IBS patients: a prospective assessment. Am J Gastroenterol. 2009; 104 ( 4 ): 912 ‐ 919.
dc.identifier.citedreferenceElsenbruch S. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro‐immune mechanisms. Brain Behav Immun. 2011; 25 ( 3 ): 386 ‐ 394.
dc.identifier.citedreferenceSweeney L, Moss‐Morris R, Czuber‐Dochan W, Meade L, Chumbley G, Norton C. Systematic review: psychosocial factors associated with pain in inflammatory bowel disease. Aliment Pharmacol Ther. 2018; 47 ( 6 ): 715 ‐ 729.
dc.identifier.citedreferenceParkman HP, Wilson LA, Hasler WL, et al. Abdominal pain in patients with gastroparesis: associations with gastroparesis symptoms, etiology of gastroparesis, gastric emptying, somatization, and quality of life. Dig Dis Sci. 2019; 64 ( 8 ): 2242 ‐ 2255.
dc.identifier.citedreferenceFass R, Fullerton S, Tung S, Mayer EA. Sleep disturbances in clinic patients with functional bowel disorders. Am J Gastroenterol. 2000; 95 ( 5 ): 1195 ‐ 2000.
dc.identifier.citedreferenceBallou S, Alhassan E, Hon E, et al. Sleep disturbances are commonly reported among patients presenting to a gastroenterology clinic. Dig Dis Sci. 2018; 63 ( 11 ): 2983 ‐ 2991.
dc.identifier.citedreferenceYang P‐L, Burr RL, Buchanan DT, Pike KC, Kamp KJ, Heitkemper MM. Indirect effect of sleep on abdominal pain through daytime dysfunction in adults with irritable bowel syndrome. J Clin Sleep Med. 2020; 16 ( 10 ): 1701 ‐ 1710.
dc.identifier.citedreferenceBuchanan DT, Cain K, Heitkemper M, et al. Sleep measures predict next‐day symptoms in women with irritable bowel syndrome. J Clin Sleep Med. 2014; 10 ( 9 ): 1003 ‐ 1009.
dc.identifier.citedreferencePatel A, Hasak S, Cassell B, et al. Effects of disturbed sleep on gastrointestinal and somatic pain symptoms in irritable bowel syndrome. Aliment Pharmacol Ther. 2016; 44 ( 3 ): 246 ‐ 258.
dc.identifier.citedreferenceBallou S, Katon J, Rangan V, et al. Brief behavioral therapy for insomnia in patients with irritable bowel syndrome: a pilot study. Dig Dis Sci. 2020; 65 ( 11 ): 3260 ‐ 3270.
dc.identifier.citedreferenceAziz I, Törnblom H, Palsson OS, Whitehead WE, Simrén M. How the Change in IBS criteria from Rome III to Rome IV impacts on clinical characteristics and key pathophysiological factors. Am J Gastroenterol. 2018; 113 ( 7 ): 1017 ‐ 1025.
dc.identifier.citedreferenceMangel AW, Wang J, Sherrill B, Gnanasakthy A, Ervin C, Fehnel SE. Urgency as an endpoint in irritable bowel syndrome. Gastroenterol Res. 2011; 4 ( 1 ): 9 ‐ 12.
dc.identifier.citedreferenceCain KC, Headstrom P, Jarrett ME, et al. Abdominal pain impacts quality of life in women with irritable bowel syndrome. Am J Gastroenterol. 2006; 101 ( 1 ): 124 ‐ 132.
dc.identifier.citedreferenceHeitkemper M, Cain KC, Shulman R, Burr R, Poppe A, Jarrett M. Subtypes of irritable bowel syndrome based on abdominal pain/discomfort severity and bowel pattern. Dig Dis Sci. 2011; 56 ( 7 ): 2050 ‐ 2058.
dc.identifier.citedreferenceNyrop KA, Palsson OS, Levy RL, et al. Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. Aliment Pharmacol Ther. 2007; 26 ( 2 ): 237 ‐ 248.
dc.identifier.citedreferenceMa C, Congly SE, Novak KL, et al. Epidemiologic burden and treatment of chronic symptomatic functional bowel disorders in the united states: a nationwide analysis. Gastroenterology. 2020; 160 ( 1 ): 88 – 98.e4.
dc.identifier.citedreferenceHod K, Ringel Y, van Tilburg MAL, Ringel‐Kulka T. Bloating in irritable bowel syndrome is associated with symptoms severity, psychological factors, and comorbidities. Dig Dis Sci. 2019; 64 ( 5 ): 1288 ‐ 1295.
dc.identifier.citedreferenceBouchoucha M, Fysekidis M, Deutsch D, Bejou B, Sabate J‐M, Benamouzig R. Biopsychosocial model and perceived constipation severity according to the constipation phenotype. Dig Dis Sci. 2020. Online ahead of print.
dc.identifier.citedreferenceAgrawal A, Whorwell PJ. Review article: abdominal bloating and distension in functional gastrointestinal disorders–epidemiology and exploration of possible mechanisms. Aliment Pharmacol Ther. 2008; 27 ( 1 ): 2 ‐ 10.
dc.identifier.citedreferenceHoughton LA, Lea R, Agrawal A, Agrawal A, Reilly B, Whorwell PJ. Relationship of abdominal bloating to distention in irritable bowel syndrome and effect of bowel habit. Gastroenterology. 2006; 131 ( 4 ): 1003 ‐ 1010.
dc.identifier.citedreferenceSingh P, Lee H‐N, Rangan V, et al. Similarities in clinical and psychosocial characteristics of functional diarrhea and irritable bowel syndrome with diarrhea. Clin Gastroenterol Hepatol. 2020; 18 ( 2 ): 399 ‐ 405.e1.
dc.identifier.citedreferenceWong RK, Palsson OS, Turner MJ, et al. Inability of the Rome III criteria to distinguish functional constipation from constipation subtype irritable bowel syndrome. Am J Gastroenterol. 2010; 105 ( 10 ): 2228 ‐ 2234.
dc.identifier.citedreferenceFord AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020; 396 ( 10263 ): 1675 ‐ 1688.
dc.working.doiNOen
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
nmo14253.pdf
Size:
595.2KB
Format:
PDF
View/Open
Name:
nmo14253_am.pdf
Size:
254.7KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.